Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2001Haemophilia

Use of ristocetin cofactor activity in the management of von Willebrand disease

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with von Willebrand disease (vWD)

Design

Review

Authors

BEBruce M. EwensteinCSL (United States)

Discussion

Loading...

Member takes

Implication

May support ristocetin cofactor-based dosing of factor VIII/vWF concentrates in von Willebrand disease; hypothesis-generating pending prospective trials.

Structured PICO

P
Population
Patients with von Willebrand disease (vWD)
I
Intervention
Factor VIII/vWF concentrates based upon the content of vWF activity as reflected in the ristocetin cofactor assay
O
Outcome
Practicability, safety, and efficacy of treatment

Treatment with factor VIII/vWF concentrates based on ristocetin cofactor assay activity appears safe and efficacious for managing von Willebrand disease, though optimal dosing requires further study.

Cite This Study

Bruce M. Ewenstein (2001) studied this question.

synapsesocial.com/papers/6a85597a35bc0eada8d5979fhttps://doi.org/10.1046/j.1365-2516.2001.00096.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition1984 · 134 citations
  2. 2Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America2001 · 44 citations
  3. 3Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study2002 · 192 citations
  4. 4Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease1992 · 77 citations
  5. 5Variant von Willebrand's Disease1980 · 509 citations